

ALLIA.143A

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : H. Zaghouani

Appl. No. 08 779,767

Filed January 7, 1997


For COMPOUNDS, COMPOSITIONS
AND METHODS FOR THE
ENDOCYTIC PRESENTATION OF
IMMUNOSUPPRESSIVE FACTORS

Examiner : P. Nolan

Group Art Unit 1644

I hereby certify that this correspondence and all marked
attachments are being deposited with the United States
Postal Service as first-class mail in an envelope addressed to
United States Patent and Trademark Office, P.O. Box 2327,
Arlington, VA 22202 on

July 9, 2002
(Date)
Daniel Hart, Reg. No. 4735



RECEIVED

JUL 17 2002

TECH CENTER 1600/2930

COPY OF PAPERS
ORIGINALLY FILED

AMENDMENT AND RESPONSE TO OFFICE ACTION

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

In response to the Office Action mailed May 21, 2002, in the above-identified application, kindly amend the application as follows.

IN THE CLAIMS:

66. (Five times amended) A composition comprising an immunoglobulin or a portion thereof linked to a protein fragment or peptide, wherein said immunoglobulin or portion thereof is capable of binding to an Fc receptor and said protein fragment or peptide comprises a T cell receptor antagonist, said composition having the property of being endocytosed by cells bearing said Fc receptor and processed by the cells to present said T cell receptor antagonist in association with endogenous MHC Class II molecules, thereby preventing T cell activation in vivo.